Uterine cervical cancer is among the main items of modern oncology. Determination of SCCA levels in blood serum of women with locally disseminated forms of uterine cervical cancer has a great significance for estimation the extent of lesions, tumor progression patterns, as well as treatment monitoring. During our study, we have determined that, before starting a specific treatment, all the patients with locally disseminated forms of cervical cancer had high serum levels of SCCA, along with suppressed anti-tumor immunity.Interestingly, high SCCA levels in blood serum proved to correlate with a decrease in anti-tumor immunity factors in those patients who showed a negative dynamics of tumor progression within one year after the therapy was performed. Meanwhile, the patients with positive post-treatment dynamics exhibited a significant decrease of SCCA levels over a year after therapy, as compared with appropriate pre-treatment values, accompanied by increase in anti-tumor immunity markers in these cases.